



Attorney Docket No.: 5440.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kauppinen et al.

Serial No.: 09/339,159

Confirmation No: 2264

Group Art Unit: 1652

Filed: June 24, 1999

Examiner: M. Rao

For: Novel Mannanases

1652 \$  
#13B  
DB  
7/11/01  
**RECEIVED**

JUL 10 2001

TECH CENTER 1600/2900

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal (in duplicate)
2. Amendment and Marked Up Version pursuant to 37 C.F.R. 1.21
3. Statement Under 37 C.F.R. 1.808

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on June 27, 2001.

Julie Tabarovsky  
(name of person mailing paper)

J. Tabarovsky  
(signature of person mailing paper)



Attorney Docket No.: 5440.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Kauppinen et al.

Serial No.: 09/339,159

Confirmation No: 2264

Group Art Unit: 1652

Filed: June 24, 1999

Examiner: M. Rao

RECEIVED

JUL 10 2001

TECH CENTER 1600/2900

For: Novel Mannanases

STATEMENT UNDER 37 C.F.R. 1.808

Commissioner for Patents  
Washington, DC 20231

Sir:


The above-captioned application refers to deposit(s) of biological material which have been made at Deutsche Sammlung von Mikroorganismen under the Budapest Treaty and assigned accession number DSM 12197.

All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the U.S. patent.

The deposit(s) will be maintained for (a) thirty years, (b) at least five years after the most recent request for the furnishing of a sample of the deposit is received by the depository, or (c) the enforceable life of the U.S. patent granted from this application, whichever is longest. If the deposited material becomes inviable during the above term, the deposited material will be replaced.

Respectfully submitted,

Date: June 27, 2001

  
\_\_\_\_\_  
Jason I. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



#14B  
DOB  
7/6/01

Attorney Docket No.: 5440.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of: Kaupinen et al.

Serial No.: 09/339,159

Group Art Unit: 1652

JUL 10 2001

Filed: June 24, 1999

Examiner: M. Rao

TECH CENTER 1600/2900

For: Novel Mannanases

AMENDMENT UNDER 37 C.F.R. 1.111

Commissioner for Patents  
Washington, DC 20231

Sir:

In response to the Office Action mailed December 27, 2000, please amend the above-captioned application as follows (a marked up version pursuant to 37 C.F.R. 1.21 is attached hereto):

IN THE CLAIMS:

Please cancel claims 4-8, 12, 14-19, 24, 25, 30, and 31 without prejudice or disclaimer.

Please substitute the following amended claims for the pending claims having the same claim numbers:

- B1
1. (Amended.) An isolated mannanase, which is
    - (a) a polypeptide encoded by the mannanase enzyme encoding part of the DNA sequence cloned into the plasmid present in Escherichia coli DSM 12197, or
    - (b) a polypeptide comprising an amino acid sequence as shown in positions 31-330 of SEQ ID NO:2, or
    - (c) a polypeptide encoded by the DNA sequence as shown in positions 91-990 or positions 91-1470 of SEQ ID NO:1, or
    - (d) an analogue of the polypeptide defined in (a) or (b) which is at least 80% homologous with said polypeptide.